Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AL0S
|
|||
| Former ID |
DIB015525
|
|||
| Drug Name |
GSK-1362885
|
|||
| Synonyms |
1362885
Click to Show/Hide
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Discontinued in Phase 1 | [1] | |
| Company |
GlaxoSmithKline plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myophosphorylase (PYGM) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01013766) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.